Seeking Alpha
Value, growth, long-term horizon, medium-term horizon
Profile| Send Message|
( followers)  

Interested in the high-growth prospects of the healthcare sector? For a closer look at some promising healthcare names, we ran a screen.

We began by screening the healthcare sector for stocks with positive market sentiment, rallying above their 20-day, 50-day, and 200-day moving averages.

We then screened for those stocks with strong sales trends, comparing growth in revenue to growth in accounts receivable. Since accounts receivable is the portion of revenue not yet received and there is no guarantee the money will ever be received, the smaller the portion of revenue made up of receivables the healthier the company's revenue.

We screened for stocks seeing faster growth in revenue than accounts receivable year-over-year, as well as accounts receivable comprising a smaller portion of current assets over the same time period.

For an interactive version of this chart, click on the image below. Analyst ratings sourced from Zacks Investment Research.

Tool provided by Kapitall.

Do you think these stocks will continue to rally higher? Use this list as a starting point for your own analysis.

List sorted by increase in revenue over the last year.

1. Human Genome Sciences Inc. (HGSI): Operates as a biopharmaceutical company. Market cap at $2.85B, most recent closing price at $14.24. The stock is trading 1.66% above its 20-day moving average (MA), 4.39% above its 50-day MA, and 35.21% above its 200-day MA. Revenue grew by 142.72% during the most recent quarter ($60.34M vs. $24.86M y/y). Accounts receivable grew by 29.97% during the same time period ($90.73M vs. $69.81M y/y). Receivables, as a percentage of current assets, decreased from 22.68% to 15.27% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

2. Cynosure, Inc. (NASDAQ:CYNO): Develops, manufactures, and markets aesthetic treatment systems to the dermatology, plastic surgery, and general medical markets. Market cap at $300.38M, most recent closing price at $23.67. The stock is trading 1.36% above its 20-day moving average, 9.80% above its 50-day MA, and 36.91% above its 200-day MA. Revenue grew by 50.23% during the most recent quarter ($39.57M vs. $26.34M y/y). Accounts receivable grew by -7.77% during the same time period ($14.25M vs. $15.45M y/y). Receivables, as a percentage of current assets, decreased from 14.11% to 11.77% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

3. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN): Engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Market cap at $19.73B, most recent closing price at $101.31. The stock is trading 1.09% above its 20-day moving average, 5.41% above its 50-day MA, and 23.17% above its 200-day MA. Revenue grew by 47.94% during the most recent quarter ($274.72M vs. $185.7M y/y). Accounts receivable grew by 32.91% during the same time period ($282.72M vs. $212.72M y/y). Receivables, as a percentage of current assets, decreased from 30.37% to 22.15% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

4. Watson Pharmaceuticals, Inc. (WPI): Engages in the development, manufacturing, marketing, sale, and distribution of generic and brand pharmaceutical products focused on urology and women's health in the United States, western Europe, Canada, Australasia, South America, and South Africa. Market cap at $10.03B, most recent closing price at $78.40. The stock is trading 2.22% above its 20-day moving average, 6.97% above its 50-day MA, and 17.99% above its 200-day MA. Revenue grew by 25.28% during the most recent quarter ($1,355.2M vs. $1,081.7M y/y). Accounts receivable grew by 6.27% during the same time period ($876M vs. $824.3M y/y). Receivables, as a percentage of current assets, decreased from 41.1% to 37.76% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

5. The Medicines Company (NASDAQ:MDCO): Provides various medicines to hospitals for advancing the treatment of critical care patients primarily in the United States and Europe. Market cap at $1.36B, most recent closing price at $24.76. The stock is trading 0.62% above its 20-day moving average, 6.21% above its 50-day MA, and 18.29% above its 200-day MA. Revenue grew by 13.47% during the most recent quarter ($135.7M vs. $119.59M y/y). Accounts receivable grew by -2.86% during the same time period ($65.96M vs. $67.9M y/y). Receivables, as a percentage of current assets, decreased from 17.43% to 10.11% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

6. Gilead Sciences Inc. (NASDAQ:GILD): Engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Market cap at $40.62B, most recent closing price at $57.77. The stock is trading 11.23% above its 20-day moving average, 14.13% above its 50-day MA, and 24.42% above its 200-day MA. Revenue grew by 12.54% during the most recent quarter ($2,405.19M vs. $2,137.25M y/y). Accounts receivable grew by -12.16% during the same time period ($1,702.82M vs. $1,938.64M y/y). Receivables, as a percentage of current assets, decreased from 31.17% to 30.53% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

7. U.S. Physical Therapy Inc. (NYSE:USPH): Operates outpatient physical and occupational therapy clinics in the United States. Market cap at $299.43M, most recent closing price at $25.21. The stock is trading 0.32% above its 20-day moving average, 3.50% above its 50-day MA, and 18.50% above its 200-day MA. Revenue grew by 10.29% during the most recent quarter ($62.58M vs. $56.74M y/y). Accounts receivable grew by 5.01% during the same time period ($31.43M vs. $29.93M y/y). Receivables, as a percentage of current assets, decreased from 67.93% to 66.7% during the most recent quarter (comparing 3 months ending 2012-03-31 to 3 months ending 2011-03-31).

8. Medtox Scientific Inc. (NASDAQ:MTOX): Provides forensic and clinical laboratory services, and offers diagnostic devices. Market cap at $242.19M, most recent closing price at $27.0. The stock is trading 0.14% above its 20-day moving average, 5.32% above its 50-day MA, and 46.51% above its 200-day MA. Revenue grew by 7.38% during the most recent quarter ($29.98M vs. $27.92M y/y). Accounts receivable grew by -0.44% during the same time period ($20.45M vs. $20.54M y/y). Receivables, as a percentage of current assets, decreased from 67.65% to 58.13% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

9. Trinity Biotech plc (NASDAQ:TRIB): Develops, manufactures, distributes, and sells diagnostic test kits and instrumentation worldwide. Market cap at $272.64M, most recent closing price at $12.60. The stock is trading 0.87% above its 20-day moving average, 5.79% above its 50-day MA, and 17.62% above its 200-day MA. Revenue grew by 6.99% during the most recent quarter ($20.81M vs. $19.45M y/y). Accounts receivable grew by -36.33% during the same time period ($15.21M vs. $23.89M y/y). Receivables, as a percentage of current assets, decreased from 20.9% to 13.88% during the most recent quarter (comparing 3 months ending 2012-06-30 to 3 months ending 2011-06-30).

*Accounting data sourced from Google Finance, all other data sourced from Finviz.

Source: 9 Rallying Healthcare Stocks Seeing Strong Sales Trends